Puma Biotech fluctuates on cancer drug update
Shares of Puma Biotechnology Inc. were volatile on Wednesday after the company said it reached an agreement with regulators on the design of a late-stage trial of its drug neratinib as a treatment for breast cancer.
Puma's agreement with the Food and Drug Administration covers the design, goals, an
read more